Elsa Maitre, Xavier Troussard*
Oncologie, Vol.24, No.1, pp. 3-24, 2022, DOI:10.32604/oncologie.2022.021490
Abstract Hairy cell leukemia (LT) accounts for 2% of all leukemias. The diagnosis is based on the presence in the blood and/
or the marrow of hairy cells expressing CD103, CD123, CD11c and CD25. The BRAFV600E mutation, a molecular
marker of the disease, is present in more than 80% of cases. LT should be distinguished from other chronic B-cell
lymphoproliferative disorders, including the variant form of hairy cell leukemia (HCL-V) and diffuse splenic red
pulp lymphoma (DSRPL). Progress has recently been made in the management of patients. The purine analogues
(PNAs) in monotherapy, deoxycoformycin (DCF) or 2-chloro-deoxyadenosine (CDA), remain the first-line… More >